Section/item	ltem No	Recommendation	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Page 2/2-4	Abstract/ Paragraph1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Page2/5-24	Abstract/ Paragraph2-3
Introduction	-			
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	Page3/3-19	Introduction/ Paragraph1-2
Objectives	3	State specific objectives, including any prespecified hypotheses	Page3/20-25	Introduction/Paragraph3
Methods				
Study design	4	Present key elements of study design early in the paper	Page3/30-33, Page4/1-14	Methods/ Paragraph1
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Page3/30-33, Page4/1-14	Methods/ Paragraph1
Participants	6	<ul> <li>(a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up</li> <li>Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls</li> <li>Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants</li> </ul>	Page4/18-27	Methods/ Paragraph2
		(b) <b>Cohort study</b> —For matched studies, give matching criteria and number of exposed and unexposed <b>Case-control study</b> —For matched studies, give matching criteria and the number of controls per case	Page4/18-27	Methods/ Paragraph2
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Page4/31-34, Page5/1-34, Page6/1-6	Methods/ Paragraph3-6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Page6/10-20	Methods/ Paragraph7
Bias	9	Describe any efforts to address potential sources of bias	Page6/24-32	Methods/ Paragraph8
Study size	10	Explain how the study size was arrived at	N/A	
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Page6/24-32	Methods/ Paragraph8

## STROBE Statement—checklist of items that should be included in reports of observational studies

	(b) Describe any methods used to examine subgroups and interactions	Page7/1-6	Methods/ Paragraph9
	(c) Explain how missing data were addressed	Page7/1-6	Methods/ Paragraph9
	(d) <b>Cohort study</b> —If applicable, explain how loss to follow-up was addressed <b>Case-control study</b> —If applicable, explain how matching of cases and controls was addressed <b>Cross-sectional study</b> —If applicable, describe analytical methods taking account of sampling strategy	Page7/1-6	Methods/ Paragraph9
	(e) Describe any sensitivity analyses	Page7/1-6	Methods/ Paragraph9
		·	·
13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Page7/10-26	Results / Paragraph1
	(b) Give reasons for non-participation at each stage	Page7/10-26	Results / Paragraph1
	(c) Consider use of a flow diagram	Page7/10-26	Results / Paragraph1
14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Page7/10-26	Results / Paragraph1
	(b) Indicate number of participants with missing data for each variable of interest	Page7/10-26	Results / Paragraph1
	(c) <b>Cohort study</b> —Summarise follow-up time (eg, average and total amount)	Page7/10-26	Results / Paragraph1
15*	Cohort study—Report numbers of outcome events or summary measures over time	Page7/10-26	Results / Paragraph1
	Case-control study—Report numbers in each exposure category, or summary measures of exposure	N/A	N/A
	Cross-sectional study—Report numbers of outcome events or summary measures	N/A	N/A
16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Page7/10-26	Results / Paragraph1
	(b) Report category boundaries when continuous variables were categorized	Page7/10-26	Results / Paragraph1
	(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Page7/10-26	Results / Paragraph1
17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Page7/10-26	Results / Paragraph1
18	Summarise key results with reference to study objectives	Page8/1-8	Results/ Paragraph1
19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Page9/19-22	Conclusion
-	14* 15* 16 17 18	(d) Cohort study—If applicable, explain how loss to follow-up was addressed Case-control study—If applicable, describe analytical methods taking account of sampling strategy         (e) Describe any sensitivity analyses         13*       (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed         (b) Give reasons for non-participation at each stage       (c) Consider use of a flow diagram         14*       (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders         (b) Indicate number of participants with missing data for each variable of interest       (c) Cohort study—Report numbers of outcome events or summary measures over time         15*       Cohort study—Report numbers of outcome events or summary measures         16       (a) Give unadjusted estimates and, if applicable, confounder-adjusted for and why they were included         (b) Report category boundaries when continuous variables were categorized       (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period         17       Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	(c) Explain how missing data were addressed       Page7/1-6         (d) Cohort study—If applicable, explain how loss to follow-up was addressed       Page7/1-6         (e) Describe any sensitivity analyses       Page7/1-6         (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed       Page7/10-26         (c) Consider use of a flow diagram       Page7/10-26         (d) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders       Page7/10-26         (b) Indicate number of participants with missing data for each variable of interest       Page7/10-26         (c) Cohort study—Report numbers in each exposure category, or summary measures of exposure       N/A         15*       Cohort study—Report numbers in each exposure category, or summary measures       N/A         16       (a) Give unadjusted estimates and, if applicable, confounders were adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were categorized       Page7/10-26         17       Report numbers in each exposure categorized       Page7/10-26         (a) Give unadjusted estimates and, if applicable, confounders were adjusted for and why they were included       Page7/10-26         17       Report category boundaries when continuous variables were categorized       Page7/10-26

Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Page8/9-34	Discussion/ Paragraph 2-3				
Generalisability	21	Discuss the generalisability (external validity) of the study results	Page9/1-15	Discussion/ Paragraph 4				
Other information								
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page9/25-27	Acknowledgments/ Paragraph1				

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

Article information: https://dx.doi.org/10.21037/apm-21-2460

\*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.